Canadian Cancer Trials Group Bulletins


Recent Publications

Canadian Cancer Trials Group SC.20 - A Phase III International Randomized Trial of Single versus Multiple Fractions for Re-Irradiation of Painful Bone Metastases

Primary results of Canadian Cancer Trials Group SC.20 demonstrated that 48% of patients with pain at sites of previously irradiated bone metastases benefit from reirradiation. The purpose of this study was to determine whether the response seen in Canadian Cancer Trials Group SC.20 is associated with patient perception of benefit. The authors found that patients responding to reirradiation of painful bone metastases experience superior QOL scores and less functional interference associated with pain and concluded that patients should be offered re-treatment for painful bone metastases in the hope of reducing pain severity as well as improving QOL and pain interference.

Chow E, Meyer RM, Chen BE, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JSY, Nabid A, Tissing-Tan CJA, Oei B, Babington S, Demas WF, Wilson CF, Wong RKS, Brundage M. Impact of Reirradiation of Painful Osseous Metastases on Quality of Life and Function: A Secondary Analysis of the Canadian Cancer Trials Group SC.20 Randomized Trial (ONLINE). J Clin Oncol 2014.

Canadian Cancer Trials Group MA.27 - A Randomized Phase III Trial of Exemestane versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer

The investigators performed a discovery case-cohort genome-wide association study (GWAS) using samples from 1071 patients, 231 cases and 840 controls, enrolled in the MA.27 breast cancer aromatase inhibitor (AI) trial to identify genetic factors involved in AI-related fractures, followed by functional genomic validation. The observations noted by the investigators may lead to the identification of novel mechanisms associated with fracture risk in postmenopausal women treated with AIs.

Liu M, Goss PE, Ingle JN, Kubo M, Furukawa Y, Batzler A, Jenkins GD, Carlson EE, Nakamura Y, Schaid DJ, Chapman JA, Shepherd LE, Ellis MJ, Khosla S, Wang L, Weinshilboum RM. Aromatase Inhibitor-Associated Bone Fractures: A Case-Cohort GWAS and Functional Genomics. Molecular Endocrinology 28: 1740-51, 2014.